Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14737140.2025.2474732 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Expression of SIRPα-Fc by oncolytic virus enhances antitumor efficacy through tumor microenvironment reprogramming.
Front Immunol
March 2025
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Oncolytic viruses (OVs) selectively replicate within tumors, directly killing cancer cells and promoting a systemic immune response by releasing tumor antigens. These features make OVs a promising approach in tumor immunotherapy, offering targeted treatment with fewer side effects. Despite these advantages, OVs are primarily administered via intratumoral injection, limiting their effectiveness for advanced, systemic cancers.
View Article and Find Full Text PDFDevelopment of an apoptotic lentogenic Newcastle disease virus strain by incorporating the p30 protein of African swine fever virus.
Virology
March 2025
Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, Assam, 781039, India. Electronic address:
Virotherapy is one of the emerging approaches for cancer treatment. Newcastle disease virus (NDV) is a well-studied avian paramyxovirus commonly isolated from birds. Typically, the virulent strains of NDV are acknowledged for their oncolytic properties.
View Article and Find Full Text PDFHarnessing State-of-the-Art Gene Therapy to Transform Oral Cancer Treatment.
Biochem Genet
March 2025
Department of Clinical Psychology, The People'S Hospital of Weifang, 151 Guangwen Street, Kuiwen District, Weifang, 26100, Shandong, China.
Oral cancer, the most prevalent type of cancer in the head and neck region, has an overall five-year survival rate of less than 50%. Key risk factors for its development include tobacco use, alcohol consumption, betel nut chewing, and infections with human papillomavirus (e.g.
View Article and Find Full Text PDFUnmasking the potential: mechanisms of neuroinflammatory modulation by oncolytic viruses in glioblastoma.
Explor Target Antitumor Ther
February 2025
Department of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran 16635148, Iran.
Glioblastoma, an aggressive and lethal brain tumor, presents enormous clinical challenges, including molecular heterogeneity, high recurrence rates, resistance to conventional therapies, and limited therapeutic penetration across the blood-brain barrier. The glioblastoma microenvironment, characterized by a dynamic interplay of cellular and non-cellular components, is a key driver of tumor growth and therapeutic resistance. Neuroinflammatory cytokines, particularly interleukins and tumor necrosis factor-alpha, play pivotal roles in this microenvironment, contributing to tumor progression and immune evasion.
View Article and Find Full Text PDFWe recently identified the F ACT- E TS-1 A ntiviral R esponse (FEAR) pathway as an interferon-independent innate immune response that restricts DNA virus replication and is countered by poxvirus-encoded A51R proteins (Rex , 2024, ). The human FEAR pathway is mediated by the FACT complex, consisting of hSpt16 and SSRP1 subunits, that remodels chromatin to activate expression of the antiviral transcription factor, ETS-1. To counter this pathway, poxvirus A51R proteins tether SUMOylated hSpt16 subunits to microtubules to prevent ETS-1 expression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!